Table of Contents Author Guidelines Submit a Manuscript
Journal of Drug Delivery
Volume 2011, Article ID 192562, 7 pages
http://dx.doi.org/10.1155/2011/192562
Research Article

Effective Delivery of PEGylated siRNA-Containing Lipoplexes to Extraperitoneal Tumours following Intraperitoneal Administration

The University of Queensland Diamantina Institute, Princess Alexandra Hospital, The University of Queensland, Woolloongabba, QLD 4102, Australia

Received 14 January 2011; Accepted 7 April 2011

Academic Editor: Hsin-I Chang

Copyright © 2011 Akul Singhania et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. C. N. Landen, W. M. Merritt, L. S. Mangala et al., “Intraperitoneal delivery of liposomal siRNA for therapy of advanced ovarian cancer,” Cancer Biology and Therapy, vol. 5, no. 12, pp. 1708–1713, 2006. View at Google Scholar · View at Scopus
  2. H. Giladi, M. Ketzinel-Gilad, L. Rivkin, Y. Felig, O. Nussbaum, and E. Galun, “Small interfering RNA inhibits hepatitis B virus replication in mice,” Molecular Therapy, vol. 8, no. 5, pp. 769–776, 2003. View at Publisher · View at Google Scholar · View at Scopus
  3. M. Díaz-Hernández, J. Torres-Peraza, A. Salvatori-Abarca et al., “Full motor recovery despite striatal neuron loss and formation of irreversible amyloid-like inclusions in a conditional mouse model of Huntington's disease,” Journal of Neuroscience, vol. 25, no. 42, pp. 9773–9781, 2005. View at Publisher · View at Google Scholar · View at Scopus
  4. S. Y. Wu and N. A. J. McMillan, “Lipidic systems for in vivo siRNA delivery,” AAPS Journal, vol. 11, no. 4, pp. 639–652, 2009. View at Publisher · View at Google Scholar · View at Scopus
  5. M. E. Davis, J. E. Zuckerman, C. H. J. Choi et al., “Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles,” Nature, vol. 464, no. 7291, pp. 1067–1070, 2010. View at Publisher · View at Google Scholar · View at Scopus
  6. K. Chaudhary, S. Haddadin, R. Nistala, and C. Papageorgio, “Intraperitoneal drug therapy: an advantage,” Current Clinical Pharmacology, vol. 5, no. 2, pp. 82–88, 2010. View at Publisher · View at Google Scholar · View at Scopus
  7. M. Ghionzoli, M. Cananzi, A. Zani et al., “Amniotic fluid stem cell migration after intraperitoneal injection in pup rats: implication for therapy,” Pediatric Surgery International, vol. 26, no. 1, pp. 79–84, 2010. View at Publisher · View at Google Scholar · View at Scopus
  8. S. Y. Wu, A. Singhania, M. Burgess et al., “Systemic delivery of E6/7 siRNA using novel lipidic particles and its application with cisplatin in cervical cancer mouse models,” Gene Therapy, vol. 18, no. 1, pp. 14–22, 2011. View at Publisher · View at Google Scholar
  9. M. Teo, “Peritoneal-based malignancies and their treatment,” Annals of the Academy of Medicine Singapore, vol. 39, no. 1, pp. 54–57, 2010. View at Google Scholar · View at Scopus
  10. D. S. Alberts, P. Y. Liu, E. V. Hannigan et al., “Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer,” The New England Journal of Medicine, vol. 335, no. 26, pp. 1950–1955, 1996. View at Publisher · View at Google Scholar · View at Scopus
  11. M. Markman, B. N. Bundy, D. S. Alberts et al., “Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the gynecologic oncology group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group,” Journal of Clinical Oncology, vol. 19, no. 4, pp. 1001–1007, 2001. View at Google Scholar · View at Scopus
  12. D. K. Armstrong, B. Bundy, L. Wenzel et al., “Intraperitoneal cisplatin and paclitaxel in ovarian cancer,” The New England Journal of Medicine, vol. 354, no. 1, pp. 34–43, 2006. View at Publisher · View at Google Scholar · View at Scopus
  13. R. F. Hwang, E. M. Gordon, W. F. Anderson et al., “Gene therapy for primary and metastatic pancreatic cancer with intraperitoneal retroviral vector bearing the wild-type p53 gene,” Surgery, vol. 124, no. 2, pp. 143–151, 1998. View at Publisher · View at Google Scholar · View at Scopus
  14. J. Deshane, G. P. Siegal, M. Wang et al., “Transductional efficacy and safety of an intraperitoneally delivered adenovirus encoding an anti-erbB-2 intracellular single-chain antibody for ovarian cancer gene therapy,” Gynecologic Oncology, vol. 64, no. 3, pp. 378–385, 1997. View at Publisher · View at Google Scholar · View at Scopus
  15. P. Rimessi, P. Sabatelli, M. Fabris et al., “Cationic PMMA nanoparticles bind and deliver antisense oligoribonucleotides allowing restoration of dystrophin expression in the mdx mouse,” Molecular Therapy, vol. 17, no. 5, pp. 820–827, 2009. View at Publisher · View at Google Scholar · View at Scopus
  16. J. G. Fewell, M. Matar, J. S. Rice et al., “Treatment of disseminated ovarian cancer using nonviral interleukin-12 gene therapy delivered intraperitoneally,” Journal of Gene Medicine, vol. 11, no. 8, pp. 718–728, 2009. View at Publisher · View at Google Scholar · View at Scopus
  17. T. J. Yeatman and A. F. Chambers, “Osteopontin and colon cancer progression,” Clinical and Experimental Metastasis, vol. 20, no. 1, pp. 85–90, 2003. View at Publisher · View at Google Scholar · View at Scopus
  18. S. Yachida, S. Jones, I. Bozic et al., “Distant metastasis occurs late during the genetic evolution of pancreatic cancer,” Nature, vol. 467, no. 7319, pp. 1114–1117, 2010. View at Publisher · View at Google Scholar
  19. X. Y. Niu, Z. L. Peng, W. Q. Duan, H. Wang, and P. Wang, “Inhibition of HPV 16 E6 oncogene expression by RNA interference in vitro and in vivo,” International Journal of Gynecological Cancer, vol. 16, no. 2, pp. 743–751, 2006. View at Publisher · View at Google Scholar · View at Scopus
  20. K. Y. Lin, F. G. Guarnieri, K. F. Staveley-O'Carroll et al., “Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen,” Cancer Research, vol. 56, no. 1, pp. 21–26, 1996. View at Google Scholar · View at Scopus
  21. C. H. Lee, Y. H. Ni, C. C. Chen, C. K. Chou, and F. H. Chang, “Synergistic effect of polyethylenimine and cationic liposomes in nucleic acid delivery to human cancer cells,” Biochimica et Biophysica Acta, vol. 1611, no. 1-2, pp. 55–62, 2003. View at Publisher · View at Google Scholar · View at Scopus
  22. S. Y. Wu, L. N. Putral, M. Liang, H. I. Chang, N. M. Davies, and N. A. J. McMillan, “Development of a novel method for formulating stable sirna-loaded lipid particles for in vivo use,” Pharmaceutical Research, vol. 26, no. 3, pp. 512–522, 2009. View at Publisher · View at Google Scholar · View at Scopus
  23. B. Romberg, W. E. Hennink, and G. Storm, “Sheddable coatings for long-circulating nanoparticles,” Pharmaceutical Research, vol. 25, no. 1, pp. 55–71, 2008. View at Publisher · View at Google Scholar · View at Scopus
  24. S. A. Johnstone, D. Masin, L. Mayer, and M. B. Bally, “Surface-associated serum proteins inhibit the uptake of phosphatidylserine and poly(ethylene glycol) liposomes by mouse macrophages,” Biochimica et Biophysica Acta, vol. 1513, no. 1, pp. 25–37, 2001. View at Publisher · View at Google Scholar · View at Scopus
  25. P. H. Sugarbaker, O. A. Stuart, and C. P. Carmignani, “Pharmacokinetic changes induced by the volume of chemotherapy solution in patients treated with hyperthermic intraperitoneal mitomycin C,” Cancer Chemotherapy and Pharmacology, vol. 57, no. 5, pp. 703–708, 2006. View at Publisher · View at Google Scholar · View at Scopus
  26. R. L. Dedrick, C. E. Myers, P. M. Bungay, and V. T. Devita Jr., “Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer,” Cancer Treatment Reports, vol. 62, no. 1, pp. 1–11, 1978. View at Google Scholar · View at Scopus
  27. A. Rippe, C. Rippe, K. Swärd, and B. Rippe, “Disproportionally low clearance of macromolecules from the plasma to the peritoneal cavity in a mouse model of peritoneal dialysis,” Nephrology Dialysis Transplantation, vol. 22, no. 1, pp. 88–95, 2007. View at Publisher · View at Google Scholar · View at Scopus
  28. P. Keshaviah, P. F. Emerson, E. F. Vonesh, and J. C. Brandes, “Relationship between body size, fill volume, and mass transfer area coefficient in peritoneal dialysis,” Journal of the American Society of Nephrology, vol. 4, no. 10, pp. 1820–1826, 1994. View at Google Scholar · View at Scopus
  29. D. S. Kohane, J. Y. Tse, Y. Yeo, R. Padera, M. Shubina, and R. Langer, “Biodegradable polymeric microspheres and nanospheres for drug delivery in the peritoneum,” Journal of Biomedical Materials Research Part A, vol. 77, no. 2, pp. 351–361, 2006. View at Publisher · View at Google Scholar · View at Scopus
  30. B. Roser, “The migration of macrophages in vivo,” in Mononuclear Phagocytes, R. van Furth, Ed., pp. 166–174, Blackwell Scientific Publications, Oxford, UK, 1970. View at Google Scholar
  31. G. Lukas, S. D. Brindle, and P. Greengard, “The route of absorption of intraperitoneally administered compounds,” Journal of Pharmacology and Experimental Therapeutics, vol. 178, no. 3, pp. 562–564, 1971. View at Google Scholar · View at Scopus
  32. M. F. Abu-Hijleh, O. A. Habbal, and S. T. Moqattash, “The role of the diaphragm in lymphatic absorption from the peritoneal cavity,” Journal of Anatomy, vol. 186, no. 3, pp. 453–467, 1995. View at Google Scholar · View at Scopus
  33. B. Rippe, “A three-pore model of peritoneal transport,” Peritoneal Dialysis International, vol. 13, no. 2, pp. S35–S38, 1993. View at Google Scholar · View at Scopus